Zhejiang Doer Biologics Co., Ltd.
Clinical trials sponsored by Zhejiang Doer Biologics Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug combo aims to shrink hard-to-treat gut tumors Results expected Apr 2027 (estimated)
- New hope for advanced cancer: experimental drug DR30206 enters human testing Results expected Jul 2027 (estimated)
-
Weekly shot aims to tame dangerous fat levels in the blood
Disease control Not yet recruitingThis Phase 3 trial tests an investigational biologic called DR10624, given as a weekly injection, in adults with severe hypertriglyceridemia (very high blood fats) who are already on standard lipid-lowering therapy. The study compares two doses of DR10624 against a placebo to see…
Phase 3 • Sponsor: Zhejiang Doer Biologics Co., Ltd. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New biologic aims to tackle stubborn high triglycerides
Disease control Not yet recruitingThis phase 3 trial tests an investigational injectable drug called DR10624 in adults with severe hypertriglyceridemia (very high blood fats) that remains high despite standard treatment. Participants continue their usual omega-3 therapy and receive weekly injections of DR10624 or…
Phase 3 • Sponsor: Zhejiang Doer Biologics Co., Ltd. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC